Trials / Completed
CompletedNCT02060188
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 385 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.
Conditions
- Microsatellite Unstable Colorectal Cancer
- Microsatellite Stable Colorectal Cancer
- Mismatch Repair Proficient Colorectal Cancer
- Mismatch Repair Deficient Colorectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Cobimetinib | Specified dose on specified days |
| DRUG | Daratumumab | Specified dose on specified days |
| DRUG | BMS-986016 | Specified dose on specified days |
Timeline
- Start date
- 2014-03-12
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
- First posted
- 2014-02-11
- Last updated
- 2025-11-06
- Results posted
- 2025-11-06
Locations
32 sites across 8 countries: United States, Australia, Belgium, Canada, France, Ireland, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02060188. Inclusion in this directory is not an endorsement.